Key Points
- Electromed Director Kathleen Skarvan sold 40,000 shares on May 15 at an average price of $35.48, totaling about $1.42 million. After the transaction, she still owned 35,622 shares, a 52.89% reduction in her holdings.
- Electromed’s stock was trading near its 12-month high, opening at $38.37 with a market cap of $317.7 million. The shares have ranged from $17.73 to $39.25 over the past year.
- Wall Street sentiment remains positive, with a consensus rating of “Buy” and a price target of $37.50. Recent calls included a buy rating from Roth Mkm, a higher target from B. Riley Financial, and a Zacks upgrade to strong-buy.
Electromed, Inc. (NYSE:ELMD - Get Free Report) Director Kathleen Skarvan sold 40,000 shares of the company's stock in a transaction dated Friday, May 15th. The stock was sold at an average price of $35.48, for a total value of $1,419,200.00. Following the sale, the director owned 35,622 shares of the company's stock, valued at $1,263,868.56. This represents a 52.89% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Electromed Price Performance
Shares of NYSE:ELMD opened at $38.37 on Wednesday. The firm has a market capitalization of $317.70 million, a PE ratio of 51.16 and a beta of 0.39. The business has a 50-day moving average of $25.95 and a two-hundred day moving average of $26.60. Electromed, Inc. has a 12 month low of $17.73 and a 12 month high of $39.25.
Institutional Investors Weigh In On Electromed
A number of large investors have recently modified their holdings of ELMD. Kestra Advisory Services LLC acquired a new stake in shares of Electromed in the fourth quarter valued at about $29,000. Thurston Springer Miller Herd & Titak Inc. acquired a new stake in shares of Electromed in the fourth quarter valued at about $43,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in shares of Electromed in the second quarter valued at about $83,000. New York State Common Retirement Fund acquired a new stake in shares of Electromed in the second quarter valued at about $103,000. Finally, SG Americas Securities LLC acquired a new stake in shares of Electromed in the fourth quarter valued at about $114,000. Institutional investors and hedge funds own 40.82% of the company's stock.
Analysts Set New Price Targets
Several brokerages have commented on ELMD. Roth Mkm restated a "buy" rating and set a $38.00 price target on shares of Electromed in a research note on Wednesday, February 11th. B. Riley Financial increased their target price on Electromed from $38.00 to $40.00 and gave the company a "buy" rating in a research note on Wednesday, May 13th. Finally, Zacks Research upgraded Electromed from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, May 13th. One research analyst has rated the stock with a Strong Buy rating and three have assigned a Buy rating to the stock. Based on data from MarketBeat, Electromed currently has a consensus rating of "Buy" and a consensus price target of $37.50.
View Our Latest Analysis on ELMD
Electromed Company Profile
(
Get Free Report)
Electromed Inc (NYSE: ELMD) develops and manufactures sleep therapy products designed to support individuals with breathing disorders such as obstructive sleep apnea. The company's core business activities include the design, production and distribution of continuous positive airway pressure (CPAP) and bilevel positive airway pressure (BiPAP) accessories. Electromed's focus on supplying both disposable and reusable components allows durable medical equipment providers to offer comprehensive therapy solutions to patients.
The company's product portfolio encompasses masks, mask cushions, headgear, tubing, filters and humidification components.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
